Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communications Arising
  • Published:

GSK-3α/β kinases and amyloid production in vivo

Abstract

Arising from C. J. Phiel, C. A. Wilson, V. M.-Y. Lee & P. S. Klein Nature 423, 435–439 (2003)10.1038/nature01640

A major unresolved issue in Alzheimer’s disease is identifying the mechanisms that regulate proteolytic processing of amyloid precursor protein (APP)—glycogen synthase kinase-3 (GSK-3) isozymes are thought to be important in this regulation. Phiel et al.1 proposed that GSK-3α, but not GSK-3β, controls production of amyloid1. We analysed the proteolytic processing of mouse and human APP in mouse brain in vivo in five different genetic and viral models. Our data do not yield evidence for either GSK-3α-mediated or GSK-3β-mediated control of APP processing in brain in vivo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: APP processing in the brains of Gsk3a n−/− and Gsk3a KO mice.
Figure 2: APP processing in the brains of Gsk3b n−/− mice.

Similar content being viewed by others

References

  1. Phiel, C. J., Wilson, C. A., Lee, V. M. & Klein, P. S. GSK-3α regulates production of Alzheimer’s disease amyloid-β peptides. Nature 423, 435–439 (2003)

    Article  ADS  CAS  Google Scholar 

  2. Ishiguro, K. et al. Glycogen synthase kinase 3β is identical to tau protein kinase I generating several epitopes of paired helical filaments. FEBS Lett. 325, 167–172 (1993)

    Article  CAS  Google Scholar 

  3. Spittaels, K. et al. GSK3β phosphorylates protein tau and rescues the axonopathy in the central nervous system of human four-repeat tau transgenic mice. J. Biol. Chem. 275, 41340–41349 (2000)

    Article  CAS  Google Scholar 

  4. Takashima, A. GSK-3 is essential in the pathogenesis of Alzheimer’s disease. J. Alzheimers Dis. 9 (Suppl.). 309–317 (2006)

    Article  CAS  Google Scholar 

  5. Terwel, D. et al. Amyloid activates GSK-3β to aggravate neuronal tauopathy in bigenic mice. Am. J. Pathol. 172, 786–798 (2008)

    Article  CAS  Google Scholar 

  6. Kaidanovich-Beilin, O. et al. Abnormalities in brain structure and behavior in GSK-3α mutant mice. Mol Brain. 2, 35 (2009)

    Article  Google Scholar 

  7. Dewachter, I. et al. Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. J. Neurosci. 22, 3445–3453 (2002)

    Article  CAS  Google Scholar 

  8. Perez-Costas, E., Gandy, J. C., Melendez-Ferro, M., Roberts, R. C. & Bijur, G. N. Light and electron microscopy study of glycogen synthase kinase-3β in the mouse brain. PLoS ONE 5, e8911 (2010)

    Article  ADS  Google Scholar 

  9. Jaworski, T. et al. AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS ONE 4, e7280 (2009)

    Article  ADS  Google Scholar 

  10. De Strooper, B. et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature 391, 387–390 (1998)

    Article  ADS  CAS  Google Scholar 

  11. Moechars, D. et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483–6492 (1999)

    Article  CAS  Google Scholar 

  12. Tanghe, A. et al. Pathological hallmarks, clinical parallels, and value for drug testing in Alzheimer’s disease of the APP[V717I] London transgenic mouse model. Int. J. Alzheimers Dis. 2010, 417314 (2010)

    PubMed  PubMed Central  Google Scholar 

  13. Jaworski, T. et al. Alzheimer’s disease: old problem, new views from transgenic and viral models. Biochim. Biophys. Acta 1802, 808–818 (2010)

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Contributions

Generation of transgenic and knockout mice, B.L., D.D., H.D., S.P. and J.R.W.; generation of AAV vectors and intracerebral injections, T.J., D.D. and S.K.; brain analysis, T.J., I.D., B.L., M.G., A.K. and P.B.; design of experiments, data analysis and figures, T.J., I.D., P.B. and F.V.L.; writing of manuscript, T.J. and F.V.L. T.J., I.D. and B.L. contributed equally to this work.

Corresponding author

Correspondence to Fred Van Leuven.

Ethics declarations

Competing interests

Competing financial interests: declared none.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jaworski, T., Dewachter, I., Lechat, B. et al. GSK-3α/β kinases and amyloid production in vivo. Nature 480, E4–E5 (2011). https://doi.org/10.1038/nature10615

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature10615

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing